{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:51:18Z","timestamp":1772711478754,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Biomedical Research Institute of Chonnam National University Hospital","award":["BCRI22024"],"award-info":[{"award-number":["BCRI22024"]}]},{"name":"Daiichi-Sankyo Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to assess the efficacy and safety of intravenous ramosetron for pain relief in patients with fibromyalgia (FM) unresponsive to conventional treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective, double-blind, placebo-controlled trial, 80 FM patients were randomly allocated to receive either placebo (n\u2009=\u200940) or ramosetron (n\u2009=\u200940) at a dosage of 0.3\u2009mg\/day intravenously for five consecutive days. The primary outcome was the reduction in pain intensity at the end of the treatment period, evaluated using a visual analogue scale (VAS). Secondary outcome measures included the FM Impact Questionnaire, Beck Depression Inventory (BDI), Multi-Dimensional Health Assessment Questionnaire (MDHAQ), EQ-5D and State-Trait Anxiety Inventory on days 5 (end of treatment), 7, 10 and 28. Safety was continuously monitored throughout the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At the end of the treatment phase, the ramosetron group demonstrated a significantly greater reduction in VAS pain scores compared with the placebo group (1.18\u2009\u00b1\u20091.60 vs 0.54\u2009\u00b1\u20091.59, P\u2009&amp;lt;\u20090.05). Additionally, the ramosetron group exhibited significant improvements in BDI (4.42\u2009\u00b1\u20095.18 vs 1.33\u2009\u00b1\u20094.87, P\u2009&amp;lt;\u20090.05) and MDHAQ pain scale (0.37\u2009\u00b1\u20090.74 vs 0.04\u2009\u00b1\u20090.52, P\u2009&amp;lt;\u20090.05) scores. However, these improvements in pain VAS and BDI scores were not sustained through day 28. The safety profile of ramosetron was favorable, with gastrointestinal symptoms, particularly constipation, being the most commonly reported adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intravenous administration of ramosetron provided safe and effective short-term relief of pain intensity in FM patients with inadequate response to standard treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae310","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T05:17:25Z","timestamp":1716527845000},"page":"2372-2378","source":"Crossref","is-referenced-by-count":1,"title":["Ramosetron as an add-on therapy for refractory fibromyalgia: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1093","volume":"63","author":[{"given":"Dong-Jin","family":"Park","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyemin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-2001","authenticated-orcid":false,"given":"Ji-Hyoun","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Kil","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Chonnam National University Medical School and Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-7355","authenticated-orcid":false,"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital , Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"2024090404221730800_keae310-B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4078\/jrd.2022.29.1.4","article-title":"Disentangling diagnosis and management of fibromyalgia","volume":"29","author":"Kang","year":"2022","journal-title":"J Rheum Dis"},{"key":"2024090404221730800_keae310-B2","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","article-title":"Nociplastic pain: towards an understanding of prevalent pain conditions","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet"},{"key":"2024090404221730800_keae310-B3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.neuropharm.2008.08.003","article-title":"The 5-HT3 receptor\u2014the relationship between structure and function","volume":"56","author":"Barnes","year":"2009","journal-title":"Neuropharmacology"},{"key":"2024090404221730800_keae310-B4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1523\/JNEUROSCI.22-03-01010.2002","article-title":"The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors","volume":"22","author":"Zeitz","year":"2002","journal-title":"J Neurosci"},{"key":"2024090404221730800_keae310-B5","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2174\/156802606778522122","article-title":"New treatment options using 5-HT3 receptor antagonists in rheumatic diseases","volume":"6","author":"Muller","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"2024090404221730800_keae310-B6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1358\/dot.2002.38.2.820104","article-title":"Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting","volume":"38","author":"Rabasseda","year":"2002","journal-title":"Drugs Today (Barc)"},{"key":"2024090404221730800_keae310-B7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00228-016-2100-7","article-title":"Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"72","author":"Song","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2024090404221730800_keae310-B8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Qi","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"2024090404221730800_keae310-B9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/acr.21931","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"65","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024090404221730800_keae310-B10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1756-185X.12640","article-title":"Cross-cultural adaptation of the Revised Korean version of the Fibromyalgia Impact Questionnaire: its association with physical function and quality of life","volume":"19","author":"Seo","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2024090404221730800_keae310-B11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s11136-004-5681-z","article-title":"Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases","volume":"14","author":"Kim","year":"2005","journal-title":"Qual Life Res"},{"key":"2024090404221730800_keae310-B12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10067-005-0049-5","article-title":"Evaluating the Korean version of the Multidimensional Health Assessment Questionnaire in patients with rheumatoid arthritis","volume":"25","author":"Lee","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2024090404221730800_keae310-B13","first-page":"77","article-title":"A standardization study of Beck Depression Inventory I\u2014Korean version (K-BDI): reliability and factor analysis","volume":"4","author":"Rhee","year":"1995","journal-title":"Kor J Psychopathol"},{"key":"2024090404221730800_keae310-B14","first-page":"69","article-title":"A study based on the standardization of the STAI for Korea","volume":"21","author":"Kim","year":"1978","journal-title":"New Med J"},{"key":"2024090404221730800_keae310-B15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejpain.2010.09.013","article-title":"A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia","volume":"15","author":"Vergne-Salle","year":"2011","journal-title":"Eur J Pain"},{"key":"2024090404221730800_keae310-B16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","article-title":"Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis","volume":"181","author":"Mascarenhas","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024090404221730800_keae310-B17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jama.2008.944","article-title":"Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis","volume":"301","author":"Hauser","year":"2009","journal-title":"JAMA"},{"key":"2024090404221730800_keae310-B18","first-page":"55","article-title":"Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain","volume":"113","author":"Haus","year":"2000","journal-title":"Scand J Rheumatol Suppl"},{"key":"2024090404221730800_keae310-B19","first-page":"49","article-title":"Efficacy and tolerability of tropisetron in primary fibromyalgia\u2014a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group","volume":"113","author":"Farber","year":"2000","journal-title":"Scand J Rheumatol Suppl"},{"key":"2024090404221730800_keae310-B20","first-page":"59","article-title":"Results of the intravenous administration of tropisetron in fibromyalgia patients","volume":"113","author":"Muller","year":"2000","journal-title":"Scand J Rheumatol Suppl"},{"key":"2024090404221730800_keae310-B21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/138945006775515491","article-title":"Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response","volume":"7","author":"Dremencov","year":"2006","journal-title":"Curr Drug Targets"},{"key":"2024090404221730800_keae310-B22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.neubiorev.2016.03.001","article-title":"5HT3 receptors: target for new antidepressant drugs","volume":"64","author":"Gupta","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"2024090404221730800_keae310-B23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2004.055251","article-title":"Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study","volume":"54","author":"Piche","year":"2005","journal-title":"Gut"},{"key":"2024090404221730800_keae310-B24","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.ALC.0000095635.46911.5D","article-title":"Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals","volume":"27","author":"Johnson","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"2024090404221730800_keae310-B25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpain.2015.06.004","article-title":"Bidirectional Association Between Depression and Fibromyalgia Syndrome: A Nationwide Longitudinal Study","volume":"16","author":"Chang","year":"2015","journal-title":"J Pain"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae310\/58307386\/keae310.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2372\/59007457\/keae310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2372\/59007457\/keae310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:25:52Z","timestamp":1725449152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2372\/7682383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,25]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae310","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,25]]}}}